Pardini, Matteo, Guida, Silvia, Primavera, Alberto et al. · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2011 · DOI
This study tested two medications in 40 ME/CFS patients without depression: amisulpride (a low-dose psychiatric medication) and fluoxetine (an antidepressant). After 12 weeks, patients taking amisulpride reported feeling less fatigued and had fewer body aches, while those taking fluoxetine saw little improvement. Both medications were well-tolerated, suggesting amisulpride might be worth exploring further as a treatment option.
Most pharmacologic treatments for ME/CFS have shown only modest benefit, making this positive finding for amisulpride noteworthy. If confirmed in larger blinded trials, amisulpride could represent a novel therapeutic approach for fatigue and somatic symptoms in non-depressed ME/CFS patients, addressing an important unmet clinical need.
This open-label study cannot establish efficacy beyond placebo effect, as neither patients nor unblinded physicians were masked to treatment assignment. The results do not prove amisulpride works for all ME/CFS patients (only those without depression were studied) and do not establish mechanism of action. Larger, double-blind, placebo-controlled trials are necessary before clinical recommendations can be made.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →